UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

H.C. Wainwright reaffirmed a Buy rating on Cartesian Therapeutics shares, maintaining the $45.00 price target, representing a ...

Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol ...

Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...

Johnson & Johnson (NYSE: JNJ) has announced promising results from its pivotal Phase 3 Vivacity-MG3 study evaluating ...

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

and resources related to Myasthenia Gravis. Our weekly newsletter covers essential topics, including cutting-edge research updates, expert interviews, treatment innovations, and resources to ...

Other common causes include Haemophilus influenzae, Chlamydia pneumoniae, and Mycoplasma pneumoniae. Antibiotic drugs, which treat bacterial infections, are the primary form of treatment for bacterial ...